CHROMADEX CORP (CDXC) Stock News

USA - NASDAQ:CDXC - US1710774076 - Common Stock

7.87 USD

-0.07 (-0.88%)

Last: 3/18/2025, 8:00:02 PM

7.87 USD

0 (0%)

After Hours: 3/18/2025, 8:00:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CDXC Latest News, Press Relases and Analysis

All

Press Releases

7 months ago - By: ChromaDex Corporation

ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025

7 months ago - By: ChromaDex Corporation

ChromaDex to Present at the 37th Annual Roth Conference

a year ago - By: Benzinga

Insights into ChromaDex's Upcoming Earnings

a year ago - By: BusinessInsider

News Image

CDXC Stock Earnings: ChromaDex Misses Revenue for Q2 2024

7 months ago - By: ChromaDex Corporation

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results

a year ago - By: InvestorPlace

CDXC Stock Earnings: ChromaDex Misses Revenue for Q2 2024

7 months ago - By: Benzinga - Mentions: AMLX WEYS OLPX HRZN ...

Earnings Scheduled For March 4, 2025

7 months ago - By: ChromaDex Corporation

ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025

9 months ago - By: ChromaDex Corporation

ChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

10 months ago - By: ChromaDex Corporation

ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category

11 months ago - By: ChromaDex Corporation

ChromaDex’s Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology’s Inaugural Longevity Supplement

a year ago - By: ChromaDex Corporation

ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide

a year ago - By: ChromaDex Corporation

ChromaDex Corporation Reports Third Quarter 2024 Financial Results

a year ago - By: ChromaDex Corporation

ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024

a year ago - By: ChromaDex Corporation

ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024

a year ago - By: ChromaDex Corporation

ChromaDex to Participate in the 17th Annual LD Micro Main Event

a year ago - By: ChromaDex Corporation

Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)

a year ago - By: ChromaDex Corporation

ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference

a year ago - By: ChromaDex Corporation

ChromaDex Appoints Ozan Pamir as Chief Financial Officer

a year ago - By: ChromaDex Corporation

ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics

a year ago - By: ChromaDex Corporation

ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions

a year ago - By: ChromaDex Corporation

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024

a year ago - By: ChromaDex Corporation

ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+

a year ago - By: ChromaDex Corporation

ChromaDex Corporation Reports Second Quarter 2024 Financial Results